Home » Topics » Hematologic, BioWorld Science

Hematologic, BioWorld Science
RSS

Triazolopyridine antiplatelet agents in the pipeline at Ortho-McNeil

March 13, 2000

BTG outlicenses factor IX gene to Avigen

March 9, 2000

FDA approves ReFacto for hemophilia A

March 8, 2000

Potent factor XIIIa inhibitor synthesized from naturally occurring cyclopropenones

March 3, 2000

Neutralase effectively reverses new anticoagulants

March 2, 2000

Antiplatelet agents under study at Chinese centers

Feb. 25, 2000

Orally active antiplatelet agents in development at Lafon

Feb. 24, 2000

Approvable letter issued by FDA for Texas Biotechnology's Novastan

Feb. 23, 2000

Immune Response synthesizes new factor VIII gene

Feb. 23, 2000

Lafon presents piperazinone-based antithrombotic agents

Feb. 22, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Jiangsu Nhwa Pharmaceutical patents new κ-opioid receptor antagonists
BioWorld Science
Jiangsu Nhwa Pharmaceutical Co. Ltd. has disclosed κ-opioid receptor antagonists that are potentially useful for the treatment of neurological disorders.